Artivion (NYSE:AORT) SVP Sells $91,080.57 in Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 2,423 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $37.59, for a total transaction of $91,080.57. Following the completion of the transaction, the senior vice president owned 43,180 shares of the company’s stock, valued at $1,623,136.20. This represents a 5.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Artivion Stock Up 1.1%

NYSE:AORT opened at $38.52 on Friday. The company’s 50-day simple moving average is $41.93 and its 200-day simple moving average is $43.02. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The stock has a market capitalization of $1.84 billion, a P/E ratio of 192.58 and a beta of 1.59.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artivion

A number of large investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd raised its position in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after buying an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Artivion in the third quarter worth $27,000. Larson Financial Group LLC increased its stake in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after acquiring an additional 563 shares during the period. USA Financial Formulas raised its holdings in shares of Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on AORT shares. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Citizens Jmp boosted their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Canaccord Genuity Group cut their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.